Abstract

Idiopathic multiple hemorrhagic sarcoma was described by Kaposi in 1872 under the title “idiopathic multiple pigment sarcoma.” At that time a number of conditions, since regarded as entities, were confused both clinically and histologically—affections such as some of the lymphoblastomas or lymphogranulomas and some of the sarcomas. Previous to 1872, the Kaposi type of sarcoma had been observed and described under several names. Kaposi placed most of the conditions under the general heading of sarcoid tumors. He described A, B, and C sarcomatoses, the B type representing what has since been known as Kaposi9s sarcoma. In recent years the term sarcoid has been limited— with the exception of the Spiegler-Fendt sarcoid, which is probably a lymphoblastoma (Zeisler; Lewis and Satenstein)—to two affections which are thought to belong to the tuberculosis group of skin diseases. Some of the original sarcoid tumors are now known to be sarcomas, while others are recognized as lymphoblastomas. Even Kaposi9s sarcoma B—idiopathic multiple hemorrhagic sarcoma—is now thought by some investigators to be more or less closely related to the lymphogranulomas. Since Kaposi9s original contributions, a voluminous literature has developed. Kren, for instance, has written a monograph of 113 pages which contains ten pages of closely crowded references. Many of the articles are argumentative. While all authors agree that the disease is a clinical and histological entity (not an etiologic entity), there is considerable controversy relative to nosology, pathogenesis, cytology, and histological minutiae. A glance at the bibliography of the affection indicates this difference of opinion, since many authors have expressed their convictions in the names they have given the disease, as shown in Table I. Regardless of the controversy over nomenclature and classification, however, the affection is generally known as Kaposi9s sarcoma, or multiple idiopathic hemorrhagic sarcoma, as suggested by Kobner in 1891.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.